• AURKB inhibitor
    • Currently no active clinical trials in the United States
    • Recommended dose: 230 mg as 24-hour continuous infusion on day 1 of 21-day cycle
    • Half-life: 12 to 26 hours
    • Common side effects: Neutropenia, leukopenia, febrile neutropenia
    (Golfier et al., 2014; Mross et al., 2010)
    Other topics in Targeted and Immunotherapy Agents